ASCRS 2024: BioTissue unveils new products

Roger Kennedy, director of marketing at BioTissue sat down to discuss the new products the company will be unveiling at this year's ASCRS meeting held in Boston, Massachusetts.

Video Transcript

Editor's note - This transcript has been edited for clarity.

David Hutton:

I'm David Hutton of Ophthalmology Times. ASCRS is holding its annual meeting this year in Boston. At the meeting, BioTissue is unveiling some new products. I'm joined today by Roger Kennedy, director of marketing for an update. Thanks for joining us, tell us what's new at BioTissue.

Roger Kennedy:

Hi, David. Thanks for having me. I'm really excited for ASCRS. Really excited to be a part of BioTissue–exciting times. Over the last couple of years, we've really dedicated a lot of effort into expanding our product portfolio. Already we've had, we have two INDs setup to match the regulatory landscape going down the biologics pathway, really excited about that and something a little bit more tangible. We're going to be doing a sneak peek at ASCRS with our new product, CAM 360. That product is going to allow for patients to have access, and ophthalmologists to have access to cryopreserved amniotic membrane technology and expand that continuum of care when looking for options to treat the disease. It's designed for comfort, something that we think we have an air of opportunity to improve on. And so all in all, we're really excited about what the possibility is going to be for this product.

David Hutton:

What can this mean for ophthalmologists and the patients they treat?
Yeah, for ophthalmologists, it's going to allow ophthalmologists to have access to a product that is going to be even more comfortable. As well as access to a product that actually has the clinical benefits of anti-inflammation, anti-scarring, anti-angiogenesis, in an amniotic membrane that is comfortable. Right now we boast being the only amniotic membrane that has the ability to make the claims, and we have the clinical evidence to do so right–that has an anti-inflammation, anti-scarring. But there's areas of opportunity when it comes to the delivery mechanisms, some additional benefits with that products that we hope that CAM 360 achieves.

David Hutton:

And when would this new product be available?

Roger Kennedy:

Great question. I don't want to say anything too definitive, but hopefully before your barbecue on Fourth of July it should be available.
And ultimately how will you gauge success of this new product.
Like I said, it's expanding the continuum of care, we really want patients that are suffering from say moderate dry eye disease. Right now, if anybody's dealing with moderate to severe dry eye disease, we feel like there's really good treatment options. And although the disease is more progressed, there's defined treatment options as you get down the continuum more mild to moderate, I think options become a little bit more scarce for a variety of reasons. And we think this is going to be another option in that mild to moderate standpoint for a patient, and it should be a pretty effective option. It should have the same benefits as cryopreserved amniotic membrane, which shows effectiveness in as little as two days lasting up to five days and three months or nine months depending on what study you reference.

David Hutton:

There certainly is a lot going on at BioTissue. Is there anything else that you'd like to update us on?

Roger Kennedy:

Meet us in the booth. If you want to learn more about it, we're obviously going to be releasing more and more information. There's a lot that can't be shared right now, but there's additional benefits to this new product as well. So we're really excited about it. Make sure you follow us. Go on our website or talk to your BioTissue rep to just be in the know right to get the latest information as to when this product is available and what exactly the product can do.